Literature DB >> 278893

Lecithin-cholesterol acyltransferase (LCAT) activity in chronic uremia.

G F Guarnieri, M Moracchiello, L Campanacci, F Ursini, L Ferri, M Valente, C Gregolin.   

Abstract

High plasma concentrations of triglycerides and low plasma concentrations of esterified cholesterol and lysolecithin, with an impaired rate of VLDL and LDL catabolism, have been reported in chronic uremic patients. An important contribution to these abnormalitites might be an impaired activity of the (LCAT). Serum LCAT activity and cholesteryl ester clearance were determined in 11 patients with chronic renal failure and in 10 controls. LCAT activity was determined by using the serum of each patient both as a source of enzyme and as a substrate ("intrinsic" activity) and was compared with the activity determined on a standard substrate ("extrinsic activity), so as to ascertain the presence of inhibitory factors in the patients' sera. Both activityes have been found to be significantly (P less than 0.01) lower in chronic uremic patients than in controls. The cholesteryl ester clearance apparently did not respond to the stimulatory effect of hypertriglyceridemia, as observed in other cases of dislipoproteinemias. The parallel decrease of both enzyme activities makes it unlikely that it is due to the presence of "uremic toxins" inhibiting the enzyme activity. LCAT synthesis in the liver is probably reduced in chronic uremia. These results suggest that in chronic uremia the VLDL fail to cooperate in their own catabolism.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 278893

Source DB:  PubMed          Journal:  Kidney Int Suppl        ISSN: 0098-6577            Impact factor:   10.545


  14 in total

Review 1.  Managing Diabetes and Cardiovascular Risk in Chronic Kidney Disease Patients.

Authors:  Dragana Lovre; Sulay Shah; Aanu Sihota; Vivian A Fonseca
Journal:  Endocrinol Metab Clin North Am       Date:  2017-12-18       Impact factor: 4.741

Review 2.  Should we use statins in all patients with chronic kidney disease without dialysis therapy? The current state of knowledge.

Authors:  Jacek Rysz; Anna Gluba-Brzózka; Maciej Banach; Andrzej Więcek
Journal:  Int Urol Nephrol       Date:  2015-03-11       Impact factor: 2.370

3.  Defect in cholesterol esterification associated with renal diseases.

Authors:  J Stribrná; M Dobiásová; V Prát; K Matousovic; J Skibová
Journal:  Int Urol Nephrol       Date:  1987       Impact factor: 2.370

Review 4.  Lipoprotein metabolism and CKD: overview.

Authors:  Philip Barter
Journal:  Clin Exp Nephrol       Date:  2013-09-20       Impact factor: 2.801

5.  Worsening of lipid metabolism after successful treatment of primary aldosteronism.

Authors:  Christian Adolf; Evelyn Asbach; Anna Stephanie Dietz; Katharina Lang; Stefanie Hahner; Marcus Quinkler; Lars Christian Rump; Martin Bidlingmaier; Marcus Treitl; Roland Ladurner; Felix Beuschlein; Martin Reincke
Journal:  Endocrine       Date:  2016-05-14       Impact factor: 3.633

Review 6.  HDL metabolism and activity in chronic kidney disease.

Authors:  Nosratola D Vaziri; Mohamad Navab; Alan M Fogelman
Journal:  Nat Rev Nephrol       Date:  2010-03-23       Impact factor: 28.314

Review 7.  [Alterations of fat metabolism in renal disease - pathogenetic mechanisms (author's transl)].

Authors:  W H Hörl; M Hörl; A Heidland
Journal:  Klin Wochenschr       Date:  1982-04-01

Review 8.  Cholesterol Metabolism in CKD.

Authors:  Allison B Reiss; Iryna Voloshyna; Joshua De Leon; Nobuyuki Miyawaki; Joseph Mattana
Journal:  Am J Kidney Dis       Date:  2015-09-01       Impact factor: 8.860

9.  In vitro stimulation of HDL anti-inflammatory activity and inhibition of LDL pro-inflammatory activity in the plasma of patients with end-stage renal disease by an apoA-1 mimetic peptide.

Authors:  Nosratola D Vaziri; Hamid Moradi; Madeleine V Pahl; Alan M Fogelman; Mohamad Navab
Journal:  Kidney Int       Date:  2009-05-27       Impact factor: 10.612

Review 10.  HDL abnormalities in nephrotic syndrome and chronic kidney disease.

Authors:  Nosratola D Vaziri
Journal:  Nat Rev Nephrol       Date:  2015-11-16       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.